Silencing miR-155–5p alleviates hippocampal damage in kainic acid-induced epileptic rats via the Dusp14/MAPK pathway

Epilepsy with recurrent seizures is characterized by neuronal damage and glial proliferation induced by brain inflammation. Recurrent seizures can lead to changes in the microRNA (miRNA) spectrum, significantly influencing the inflammatory response of microglia. MiR-155–5p, as a pro-inflammatory miRNA, is increased in the epileptic brain. However, its specific role in acute seizures remains unknown. The study aimed to develop a new strategy for treating epilepsy by investigating how silencing of miR-155–5p initiated its anticonvulsive mechanism. The level of miR-155–5p was up-regulated in the hippocampus of epileptic immature rats induced by kainic acid (KA). The use of antago-miR-155–5p exerted significant beneficial effects on the seizure scores, brain discharges and cognition in immature rats following KA-induced epilepsy. Antago-miR-155–5p also inhibited neuron damage and microglial activation. Moreover, the silencing of miR-155–5p significantly inhibited the Dual-specificity phosphatase 14 (Dusp14)/ mitogen-activated protein kinase (MAPK) axis in vivo. MiR-155–5p interacted with dusp14 to regulate MAPK signaling way expression, verified by a dual-luciferase reporter assay. The results suggested that the silencing of miR-155–5p might reduce hippocampal damage in epileptic immature rats induced by KA via Dusp14/MAPK signaling way. This implied that miR-155–5p could serve as a therapeutic tool to prevent the development of epilepsy. •Antago-miR-155–5p decreased seizures induced by KA.•Antago-miR-155–5p inhibited neuronal damage and microglial activation.•Antago-miR-155–5p reduced cognition impairment in immature epileptic rats.•Antago-miR-155–5p regulated Dusp14/MAPK following KA-induced seizures.